Pyxis Oncology, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Pyxis Oncology, Inc. (PYXS) is a clinical-stage biotechnology company that develops antibody-drug conjugates and immunotherapies targeting difficult-to-treat solid tumors. The company offers a pipeline of product candidates including PYX-201, a lead investigational ADC comprising human immunoglobulin G1 targeting extradomain-B fibronectin in Phase 1 trials for relapsed or refractory solid tumors such as head and neck squamous cell carcinoma; PYX-106, a Siglec-15-targeting monoclonal antibody in Phase 1 for advanced solid tumors; PYX-107, a CD40 agonist monoclonal antibody in Phase 2 for soft tissue sarcomas, esophageal and gastroesophageal junction cancers, and pancreatic ductal adenocarcinoma; PYX-203, an ADC licensed from Pfizer Inc.; and additional candidates leveraging its proprietary Flexible Antibody Conjugation Technology platform combined with the APXiMAB antibody-discovery platform. Pyxis Oncology, founded in 2018 and headquartered in Boston, Massachusetts, operates primarily in the United States with a focus on oncology therapeutics for patients with advanced cancers. Recent strategic developments include the 2023 acquisition of Apexigen, adding a validated Phase 2-ready antibody platform and expanding ADC capabilities while maintaining cash runway into 2026; in-licensing deals with Pfizer for ADC candidates like PYX-201 and PYX-203, and with Biosion USA for PYX-106; positive November 2024 Phase 1 data for PYX-201 showing 50% objective response rate in head and neck squamous cell carcinoma; and December 2024 portfolio prioritization to focus resources on PYX-201 monotherapy and combination trials, including with Keytruda in front-line settings, while deprioritizing PYX-106.
Company News
Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head Analysis
Pyxis Oncology: Better Runway Is Bullish For MICVO's Remaining R&D
Pyxis Oncology Announces Closing of Up to $282.6 Million Public Offering
Critical Survey: Pyxis Oncology (NASDAQ:PYXS) versus Inovio Pharmaceuticals (NASDAQ:INO)
Pyxis Oncology Announces Pricing of Up to $282.6 Million Public Offering
Pyxis Oncology Announces Proposed Public Offering
Critical Analysis: Pyxis Oncology (NASDAQ:PYXS) vs. ProKidney (NASDAQ:PROK)
Alumis (NASDAQ:ALMS) & Pyxis Oncology (NASDAQ:PYXS) Head-To-Head Review
Pyxis Oncology, Inc. (PYXS) Discusses MICVO Monotherapy Phase I Clinical Data in Head and Neck Squamous Cell Carcinoma Transcript
Pyxis Oncology Analyst Flags Key Safety Liabilities from Cancer Drug
Pyxis Oncology Announces Positive Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology to Host Webcast to Present Updated Data from Phase 1 Monotherapy Study of Micvotabart Pelidotin (MICVO) in Second-Line and Beyond Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (2L+ R/M HNSCC)
Pyxis Oncology Appoints Thomas Civik Chief Executive Officer and Chairman of the Board
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Reports Second Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones
Pyxis Oncology Reports First Quarter 2026 Financial Results and Advances MICVO Toward Key 2026 Clinical Milestones
Pyxis Oncology to Participate in Upcoming Investor Conferences
Pyxis Oncology Appoints Nelson Azoulay as Chief Business Officer